Cecilia Avila
Medical · Astoria, NYNPI 1730424284
Payments from drug & device makers
Across 241 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$792
- Novo Nordisk$783
- Lilly USA, LLC$641
- Amgen$523
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$481
- Amarin Pharma, Inc.$269
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,07898%
- Education$1212%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $792 |
| Novo Nordisk | 37 | $783 |
| Lilly USA, LLC | 31 | $641 |
| Amgen | 18 | $523 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $481 |
| Amarin Pharma, Inc. | 18 | $269 |
| GSK | 10 | $220 |
| Astellas Pharma US Inc | 6 | $206 |
| Exact Sciences | 6 | $169 |
| Ironwood Pharmaceuticals, Inc | 4 | $91 |
| Phathom Pharmaceuticals, Inc. | 4 | $91 |
| Pfizer | 4 | $85 |
| Merck | 4 | $85 |
| Ardelyx, Inc. | 3 | $85 |
| Johnson & Johnson | 3 | $80 |
| AstraZeneca | 3 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $74 |
| Novartis | 4 | $71 |
| Phadia US Inc. | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Genentech USA, Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Boehringer Ingelheim | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Intuity Medical Inc | 1 | $16 |
| Seqirus USA Inc | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,198 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 69 | $110,560 |
| TrulicityDulaglutide | 50 | $84,642 |
| OzempicSemaglutide | 66 | $77,912 |
| VascepaIcosapent Ethyl | 170 | $77,176 |
| MounjaroTirzepatide | 43 | $64,137 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 68 | $60,349 |
| JardianceEmpagliflozin | 41 | $46,042 |
| SynjardyEmpagliflozin/Metformin Hcl | 38 | $43,096 |
| LinzessLinaclotide | 41 | $37,064 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $36,944 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 35 | $36,817 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $25,990 |
| FarxigaDapagliflozin Propanediol | 25 | $19,746 |
| TradjentaLinagliptin | 14 | $19,548 |
| RestasisCyclosporine | 18 | $17,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Trijardy Xr, Tradjenta | $22 | $205,852196 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $641 | $148,77993 claims |
| AmgenProlia | $523 | $110,56069 claims |
| Novo NordiskOzempic | $783 | $77,91266 claims |
| AbbVieLinzess, Restasis | $792 | $54,32759 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $41 | $36,94427 claims |
| MerckJanumet | $85 | $25,99028 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $220 | $24,78349 claims |
| AstraZenecaFarxiga | $77 | $19,74625 claims |
| Astellas Pharma US IncMyrbetriq | $206 | $16,94321 claims |
| Johnson & JohnsonXarelto | $80 | $11,04412 claims |
| PfizerEliquis | $85 | $9,83014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Astoria
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.